These three top companies have solid catalyst potential and already have shown good clinical results on their leading assets.
Lee Jackson Alexion Pharmaceuticals watched its shares make a solid gain on Thursday after the firm announced positive results from its late-stage trial of ALXN1210.
Chris Lange Tuesday was a down day for the broad U.S. markets. At first all three major indices started out positive, but over the course of the day each one turned south. Again, most…
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big…
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Credit Suisse sees tax reform sparking a wave of mergers in the emerging pharmaceuticals space, which could produce sector outperformance. The firm is cautiously optimistic on this front.
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
The top analyst upgrades, downgrades and other research calls from Thursday include Alphabet, Avon, Bank of America, Intel, Roku, Snap and Western Digital.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should…
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
A new RBC report is reasonably positive on the biotech sector for the coming year. These eight top picks for 2018 all have the potential for big upside moves.
The top analyst upgrades, downgrades and other research calls from Tuesday include Altria, Apple, General Motors, Procter & Gamble and Walmart.
